Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

eye disease

POPULAR ARTICLES

Pharmaceutical Investing

Clearside Biomedical Completes Enrollment for Phase 1/2 Trial

Medical Device Investing

TearLab Osmolarity System Receives Mexican Regulatory Approval

Clearside Biomedical Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™

LATEST ARTICLES

Ocular Therapeutix™ Announces Successful Topline Results from Phase 3 Clinical Trial of DEXTENZA™

Nicox Receives Complete Response from FDA Related for AC-170

Ocular Therapeutix™ Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP

Will GenSight's Product Candidate, GS010, Boost the Bottom Line?

Pharmaceutical Investing

Pharmaceutical Investing

Aerie Pharmaceuticals Sees Stock Soar

Ocular Therapeutix™ Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS)

Biotech Investing

SeeThru Equity Initiates Coverage of Q BioMed Inc. Price Target $3.85

Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease

Latest News

Westport Announces Annual General and Special Meeting and Timing of Q1 2025 Financial Results

Finlay Minerals Enters into Earn-In Agreements with Freeport for its PIL & ATTY Properties

Canadian Investment Regulatory Organization Trade Resumption - FYL

Finlay Minerals Enters into Earn-In Agreements with Freeport for its PIL & ATTY Properties

Forte Minerals Engages Trion Communications GmbH for European Investor Awareness